Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 2
2023 pubmed 1 citations

Activated mesenchymal stem cells increase drug susceptibility of methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.

Esfandiary. Reza R; Saeedi. Pardis P; Saffarian. Parvaneh P; Halabian. Raheleh R; Fooladi. Abbas Ali Imani AAI

Key Findings

  • Low‑dose antibiotics (1‑2 µg/mL) can precondition mesenchymal stem cells without harming them
  • Preconditioned stem cells kill MRSA and P. aeruginosa more effectively in lab tests

Practical Outcomes

  • The study points to a potential strategy for enhancing innate immunity by raising LL‑37 levels, but it’s currently limited to cell‑culture experiments. For biohackers, it suggests that future therapies might involve safe ways to boost LL‑37, though no actionable protocol exists yet.

Summary

Scientists discovered that exposing stem cells to tiny amounts of certain antibiotics makes the cells produce more natural antimicrobial peptides like LL‑37, which helps kill tough bacteria such as MRSA and Pseudomonas. While this shows a possible way to boost the body's own defenses, the method involves lab‑grown stem cells and isn’t something you can directly apply at home yet.

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa are major causes of hospital-acquired infections and sepsis. Due to increasing antibiotic resistance, new treatments are needed. Mesenchymal stem cells (MSCs) have antimicrobial effects, which can be enhanced by preconditioning with antibiotics. This study investigated using antibiotics to strengthen MSCs against MRSA and P. aeruginosa. MSCs were preconditioned with linezolid, vancomycin, meropenem, or cephalosporin. Optimal antibiotic concentrations were determined by assessing MSC survival. Antimicrobial effects were measured by minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC), and antimicrobial peptide (AMP) gene expression. Optimal antibiotic concentrations for preconditioning MSCs without reducing viability were 1 μg/mL for linezolid, meropenem, and cephalosporin and 2 μg/mL for vancomycin. In MIC assays, MSCs preconditioned with linezolid, vancomycin, meropenem, or cephalosporin inhibited MRSA or P. aeruginosa growth at lower concentrations than non-preconditioned MSCs (p ≤ 0.001). In MBC assays, preconditioned MSCs showed enhanced bacterial clearance compared to non-preconditioned MSCs, especially when linezolid and vancomycin were used against MRSA (p ≤ 0.05). Preconditioned MSCs showed increased expression of genes encoding the antimicrobial peptide genes hepcidin and LL-37 compared to non-preconditioned MSCs. The highest hepcidin expression was seen with linezolid and vancomycin preconditioning (p ≤ 0.001). The highest LL-37 expression was with linezolid preconditioning (p ≤ 0.001). MSCs' preconditioning with linezolid, vancomycin, meropenem, or cephalosporin at optimal concentrations enhances their antimicrobial effects against MRSA and P. aeruginosa without compromising viability. This suggests preconditioned MSCs could be an effective adjuvant treatment for antibiotic-resistant infections. The mechanism may involve upregulation of AMP genes.

Study Information

Provider

pubmed

Year

2023

Date

2023-11-04T00:00:00.000Z

DOI

10.1007/s12223-023-01099-z

Citations

1

References

41